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The risk of dying is increased in many illnesses, but the 
mortality associated with chronic fatigue syndrome is 
relatively unexplored. In The Lancet, Emmert Roberts 
and colleagues1 report results from a case register study 
that linked the clinical details of more than 2000 people 
with chronic fatigue syndrome presenting to a specialist 
clinic (in London and the south of England) with 
mortality outcomes over 7 years. This is the largest 
study of its type so far, and used a robust case deﬁ nition. 
The researchers noted that the overall risk of death in 
patients with chronic fatigue syndrome seemed no 
diﬀ erent from the risk in the general population. Cancer 
mortality was also similar. However, the ﬁ ndings for 
suicide deaths were striking—ﬁ ve people died during the 
7-year period. Based on the suicide rate in the general 
population of England and Wales, the expected number 
would have been less than one death by suicide. In other 
words, suicide risk was increased almost seven-fold. 
A previous US study2 reported an increase in suicide 
mortality in people with fatigue symptoms, but was too 
small to show an increased suicide risk in those who met 
the criteria for chronic fatigue syndrome.
The results of the current study are potentially very 
important but need to be interpreted with caution. 
The study was quite small for an investigation of 
mortality (n=2147 patients of whom 17 died). This small 
sample meant that the stratiﬁ ed analyses in particular 
(investigation of the risk of death in sex, age, diagnostic, 
and deprivation subgroups) lacked statistical power. The 
increased suicide mortality (sex-standardised mortality 
ratio 6·85, 95% CI 2·22–15·98; p=0·002) was based 
on just a few deaths and the conﬁ dence intervals were 
wide. Two fewer suicide deaths would have meant that 
the ﬁ ndings were no longer signiﬁ cant.
The cohort itself was well deﬁ ned but consisted of people 
who attended a national specialist centre run jointly by 
general medical and mental health service providers. 
This could mean that participants were representative 
of people with more severe or complex chronic fatigue 
syndrome, and the mortality ﬁ ndings might not be 
applicable to people with the disorder in primary care.
The researchers deﬁ ned suicide deaths using the WHO 
International Classiﬁ cation of Diseases (ICD-10) codes 
corresponding to self-inﬂ icted deaths (X60–84). Some 
suicide deaths could have been missed—eg, a proportion 
of those coded as accidental hangings or poisonings.3 
Undetermined deaths (Y10–34) are also conventionally 
included as suicide in UK studies and oﬃ  cial statistics.4 
Our understanding is that there were no such deaths in 
this cohort.
Finally, the risk of suicide was calculated by comparing 
the recorded number of deaths with the number that 
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would be expected if the age and sex-speciﬁ c rates in the 
chronic fatigue syndrome cohort matched those in the 
general population in England and Wales. However, the 
catchment population for the chronic fatigue syndrome 
clinic (largely London and the south of England) might 
not be typical of the wider population. The investigators 
suggest that on the basis of a previous study, overall 
mortality estimates in people with mental illness are 
not appreciably diﬀ erent if rates are standardised to 
the London population rather than the population of 
England and Wales.5 However, suicide mortality might 
be diﬀ erent. National data published in 2015 reported 
annual rates of suicide of 7·9 per 100 000 in London 
versus 10·7 per 100 000 in England and 15·6 per 100 000 
in Wales.4 Therefore, it could be that the actual expected 
number of deaths is lower than the number used in 
this study, and so perhaps the real risks (as indicated 
by the standardised mortality rates standardised to the 
local population) might be even higher. However, it is 
diﬃ  cult to be certain of this because it was not possible 
to precisely specify the catchment population.
We agree with the researchers that the high relative 
risk of suicide is unlikely to be a chance ﬁ nding. We need 
future studies in larger, general population cohorts to 
replicate or refute the associations reported in this study 
and explore possible risk factors such as physical6 and 
psychiatric comorbidities.7 Of course each suicide death 
is an individual tragedy but we should also bear in mind 
that even if these estimates are accurate, the absolute risk 
of suicide remains relatively low—less than one suicide 
death per 1000 people with chronic fatigue syndrome per 
year. The mechanism by which chronic fatigue syndrome 
might increase suicide risk remains unclear. It could be 
related to impairment of functioning and disruption 
to daily life. Previous ﬁ ndings have shown that suicide 
might be more likely if people have a personal contact 
with someone who has died by suicide.8 We cannot rule 
out a clustering eﬀ ect in this study; some of the people 
who died by suicide might have known each other. 
Perhaps the most plausible explanation though is the one 
the researchers have explored—depression is a risk factor 
for suicide in people with chronic fatigue syndrome just 
as it is in the general population.9 Identiﬁ cation and 
treatment of depression could therefore help.
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“You are lucky Gordon, to have a controller who knows how 
to run railways.”
Flying Scotsman, Thomas the Tank Engine, Wilbert Awdry
As the medical world began to understand the bacterial 
nature of infection, development of the hypodermic 
syringe in the mid 1800s led to opioids becoming 
important in pain management. Yet, today, 80% of the 
world’s population lack access to morphine,1 a medicine 
included in WHO’s ﬁ rst essential medicine list in 1977,2 
whereas increases in opioid consumption have occurred 
in most high-income countries.3 Stefano Berterame and 
colleagues outlining this inequity and the continued 
absence of progress in improving access in The Lancet 
Increasing worldwide access to medical opioids
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